This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. ACTU, CYBN, LFVN, AARD, NBTX, DMAC, TNGX, ACIU, DERM, and PBYIShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Actuate Therapeutics (ACTU), Cybin (CYBN), LifeVantage (LFVN), Aardvark Therapeutics (AARD), Nanobiotix (NBTX), DiaMedica Therapeutics (DMAC), Tango Therapeutics (TNGX), AC Immune (ACIU), Journey Medical (DERM), and Puma Biotechnology (PBYI). These companies are all part of the "medical" sector. Vital Therapies vs. Actuate Therapeutics Cybin LifeVantage Aardvark Therapeutics Nanobiotix DiaMedica Therapeutics Tango Therapeutics AC Immune Journey Medical Puma Biotechnology Vital Therapies (NASDAQ:VTL) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends. Which has preferable earnings & valuation, VTL or ACTU? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/AActuate TherapeuticsN/AN/A-$24.75MN/AN/A Does the media favor VTL or ACTU? In the previous week, Actuate Therapeutics had 7 more articles in the media than Vital Therapies. MarketBeat recorded 7 mentions for Actuate Therapeutics and 0 mentions for Vital Therapies. Actuate Therapeutics' average media sentiment score of 0.27 beat Vital Therapies' score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Vital Therapies Neutral Actuate Therapeutics Neutral Do analysts prefer VTL or ACTU? Actuate Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 129.05%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Vital Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor VTL or ACTU? Vital Therapies received 367 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 74.40% of users gave Vital Therapies an outperform vote. CompanyUnderperformOutperformVital TherapiesOutperform Votes36974.40% Underperform Votes12725.60% Actuate TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Is VTL or ACTU more profitable? Actuate Therapeutics' return on equity of 0.00% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% Actuate Therapeutics N/A N/A N/A Do institutionals & insiders believe in VTL or ACTU? 15.5% of Vital Therapies shares are owned by institutional investors. 33.9% of Vital Therapies shares are owned by company insiders. Comparatively, 69.3% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryActuate Therapeutics beats Vital Therapies on 10 of the 12 factors compared between the two stocks. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.30M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.31%P/E RatioN/A7.1422.1418.40Price / SalesN/A238.89389.70101.30Price / CashN/A65.6738.2034.62Price / Book3.936.266.664.18Net Income-$41.47M$142.48M$3.21B$247.71M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$1.14+3.6%N/A-11.3%$48.30MN/A0.0010ACTUActuate TherapeuticsN/A$8.37+4.6%$20.00+138.9%N/A$163.48MN/A0.0010Analyst ForecastNews CoverageCYBNCybin1.6662 of 5 stars$7.29-0.8%$86.00+1,079.7%N/A$156.57MN/A-1.6650News CoverageLFVNLifeVantage3.9568 of 5 stars$12.38-7.8%$30.50+146.4%+105.3%$155.38M$212.15M22.11260Upcoming EarningsPositive NewsAARDAardvark TherapeuticsN/A$7.12+1.7%$31.50+342.4%N/A$154.48MN/A0.0018NBTXNanobiotix1.7698 of 5 stars$3.23-1.8%$8.00+147.7%-44.1%$152.24M$-11,609,000.000.00100DMACDiaMedica Therapeutics1.7877 of 5 stars$3.53-0.3%$8.00+126.6%+70.2%$151.28MN/A-6.3020News CoveragePositive NewsTNGXTango Therapeutics1.9024 of 5 stars$1.38+7.0%$12.33+793.7%-81.2%$149.19M$42.07M-1.1790ACIUAC Immune2.3035 of 5 stars$1.48flat$12.00+710.8%-30.0%$148.61M$27.31M-3.22140Positive NewsDERMJourney Medical2.8103 of 5 stars$6.33+1.3%$9.88+56.0%+122.4%$146.25M$56.13M-6.7390PBYIPuma Biotechnology3.493 of 5 stars$2.86flat$7.00+144.8%-37.7%$141.89M$230.47M5.96200Analyst UpgradeNews Coverage Related Companies and Tools Related Companies ACTU Competitors CYBN Competitors LFVN Competitors AARD Competitors NBTX Competitors DMAC Competitors TNGX Competitors ACIU Competitors DERM Competitors PBYI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTL Stock Free VTL Stock Alerts